Veerhealth Care Ltd
Incorporated in 1992, Veer Healthcare Ltd (formerly Niyati Leasing Ltd) is engaged in
the business of trading and manufacturing and marketing research based ayurvedic medicines
- Market Cap ₹ 40.6 Cr.
- Current Price ₹ 20.3
- High / Low ₹ 23.8 / 11.8
- Stock P/E 51.4
- Book Value ₹ 11.4
- Dividend Yield 0.00 %
- ROCE 3.14 %
- ROE 1.77 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company's working capital requirements have reduced from 194 days to 135 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 31.5%
- Company has a low return on equity of 3.88% over last 3 years.
- Earnings include an other income of Rs.1.02 Cr.
- Promoter holding has decreased over last 3 years: -12.9%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.52 | 1.33 | 2.14 | 1.89 | 5.17 | 5.98 | 11.72 | 10.62 | 9.64 | 13.28 | 13.22 | 16.67 | 21.35 | |
| 3.47 | 1.48 | 2.16 | 2.25 | 5.29 | 5.54 | 11.04 | 10.56 | 10.46 | 12.78 | 12.61 | 16.21 | 19.77 | |
| Operating Profit | 0.05 | -0.15 | -0.02 | -0.36 | -0.12 | 0.44 | 0.68 | 0.06 | -0.82 | 0.50 | 0.61 | 0.46 | 1.58 |
| OPM % | 1.42% | -11.28% | -0.93% | -19.05% | -2.32% | 7.36% | 5.80% | 0.56% | -8.51% | 3.77% | 4.61% | 2.76% | 7.40% |
| 0.01 | 0.48 | 0.38 | 0.72 | 0.72 | 0.29 | 0.48 | 1.20 | 1.67 | 1.24 | 1.39 | 1.22 | 1.02 | |
| Interest | 0.00 | 0.06 | 0.13 | 0.10 | 0.07 | 0.03 | 0.19 | 0.22 | 0.09 | 0.00 | 0.01 | 0.26 | 0.44 |
| Depreciation | 0.02 | 0.11 | 0.21 | 0.23 | 0.27 | 0.32 | 0.32 | 0.47 | 0.52 | 0.62 | 0.71 | 0.91 | 1.20 |
| Profit before tax | 0.04 | 0.16 | 0.02 | 0.03 | 0.26 | 0.38 | 0.65 | 0.57 | 0.24 | 1.12 | 1.28 | 0.51 | 0.96 |
| Tax % | 25.00% | 62.50% | 100.00% | 33.33% | 42.31% | 57.89% | 50.77% | 35.09% | 129.17% | -41.07% | 68.75% | 23.53% | |
| 0.03 | 0.06 | 0.01 | 0.02 | 0.14 | 0.16 | 0.32 | 0.38 | -0.07 | 1.58 | 0.41 | 0.39 | 0.79 | |
| EPS in Rs | 0.02 | 0.04 | 0.01 | 0.01 | 0.10 | 0.12 | 0.23 | 0.27 | -0.05 | 0.79 | 0.21 | 0.20 | 0.40 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 7% |
| 3 Years: | 20% |
| TTM: | 48% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 4% |
| 3 Years: | 96% |
| TTM: | 1417% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 40% |
| 3 Years: | 27% |
| 1 Year: | 47% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 3% |
| 3 Years: | 4% |
| Last Year: | 2% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.93 | 6.93 | 6.93 | 6.93 | 6.93 | 6.93 | 6.93 | 6.93 | 6.93 | 10.00 | 20.00 | 20.00 | 20.00 |
| Reserves | 5.81 | 5.86 | 5.88 | 5.92 | 6.17 | 6.35 | 6.82 | 7.11 | 7.02 | 11.43 | 1.84 | 2.22 | 2.71 |
| 0.00 | 1.01 | 1.08 | -0.17 | 1.21 | 0.94 | 2.48 | 1.73 | 0.00 | 0.00 | 0.00 | 4.91 | 4.54 | |
| 0.18 | 0.24 | 0.23 | 0.37 | 0.42 | 1.94 | 1.76 | 2.96 | 6.20 | 3.82 | 6.28 | 6.65 | 6.79 | |
| Total Liabilities | 12.92 | 14.04 | 14.12 | 13.05 | 14.73 | 16.16 | 17.99 | 18.73 | 20.15 | 25.25 | 28.12 | 33.78 | 34.04 |
| 4.90 | 2.07 | 2.71 | 2.52 | 5.54 | 5.46 | 9.45 | 9.48 | 10.54 | 12.01 | 11.97 | 19.87 | 23.23 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 2.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| 8.02 | 11.97 | 11.41 | 10.53 | 8.95 | 8.51 | 8.54 | 9.25 | 9.61 | 13.24 | 16.15 | 13.91 | 10.78 | |
| Total Assets | 12.92 | 14.04 | 14.12 | 13.05 | 14.73 | 16.16 | 17.99 | 18.73 | 20.15 | 25.25 | 28.12 | 33.78 | 34.04 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.88 | -3.73 | 0.00 | 1.69 | 1.76 | 1.98 | -0.36 | 1.00 | 1.81 | -0.70 | 2.90 | -0.39 | |
| -4.26 | 3.85 | -0.01 | -0.44 | -3.02 | -1.90 | -1.67 | -0.09 | -1.09 | -1.79 | -0.28 | -8.20 | |
| 0.00 | 0.00 | 0.00 | -1.33 | 1.31 | 0.02 | 1.85 | -0.83 | -0.42 | 5.69 | -5.99 | 9.52 | |
| Net Cash Flow | -0.38 | 0.12 | -0.01 | -0.08 | 0.06 | 0.10 | -0.17 | 0.09 | 0.30 | 3.21 | -3.37 | 0.92 |
| Free Cash Flow | -0.88 | -1.02 | -0.76 | 1.66 | -1.78 | -0.21 | -2.48 | 0.50 | 0.23 | -2.79 | 2.22 | -9.20 |
| CFO/OP | 7,760% | 2,533% | 50% | -253% | -1,550% | 480% | -44% | 2,050% | -226% | -100% | 523% | -65% |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 8.30 | 255.23 | 151.80 | 117.80 | 64.95 | 45.17 | 29.27 | 52.93 | 58.31 | 50.57 | 108.23 | 70.28 |
| Inventory Days | 11.66 | 230.00 | 444.35 | 477.31 | 93.49 | 77.82 | 54.35 | 76.21 | 102.76 | 103.21 | 55.97 | 78.12 |
| Days Payable | 10.50 | 55.00 | 31.74 | 68.63 | 18.90 | 145.44 | 37.12 | 42.24 | 112.46 | 21.75 | 86.35 | 83.89 |
| Cash Conversion Cycle | 9.46 | 430.23 | 564.41 | 526.48 | 139.54 | -22.46 | 46.51 | 86.90 | 48.61 | 132.03 | 77.85 | 64.52 |
| Working Capital Days | 474.91 | 2,121.39 | 1,048.95 | 1,597.12 | 393.95 | 8.55 | 145.44 | 177.34 | 127.60 | 158.31 | 288.52 | 134.88 |
| ROCE % | 0.31% | -0.15% | 1.08% | 0.98% | 2.45% | 2.87% | 5.52% | 4.94% | 2.22% | 6.33% | 5.96% | 3.14% |
Insights
In beta| Mar 2016 | Mar 2018 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Manufacturing Facility - Constructed Area Sq. Ft. |
|
|||
| Manufacturing Facility - Total Plot Area Sq. Ft. |
||||
| Revenue Mix - Contract Manufacturing % |
||||
| Revenue Mix - Exports % |
||||
| Revenue Mix - Own Brand (Ayuveer) % |
||||
| Capacity Utilization % |
||||
| Number of Registered Products on GeM Portal Number |
||||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Submission of newspaper publication for notice of the postal ballot for the issuance of securities to "promoters" and "non-promoters group."
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 2d
-
Announcement under Regulation 30 (LODR)-Raising of Funds
28 Mar - Board approved preferential issue of fully convertible warrants aggregating Rs.21 crore; shareholder approval via postal ballot pending.
-
Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Veerhealth Care Limited ('Company') In Accordance With Regulation 30 Of The SEBI (LODR) Regulations, 2015 ('Listing Regulations')
28 Mar - Board approved preferential issue of fully convertible warrants aggregating Rs.21 crore; shareholder approval sought (28 Mar 2026).
- Closure of Trading Window 26 Mar
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Feb 2026TranscriptAI SummaryPPT
-
Feb 2026TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
Sep 2024TranscriptAI SummaryPPT
-
Jun 2024Transcript PPT
-
Feb 2024TranscriptPPT
Service Offered[1]
Contract Manufacturing, White Labelling, Product Development and Custom Formulation